GSK biologic approved for asthma
GSK Plc has received US approval for a new biologic to treat severe asthma, a disease driven high levels of white blood cells in the airwaves which can lead to inflammation and a shortness of breath. The Food and Drug Administration decision, announced on 16 December, will introduce a new drug to the market requiring dosing only twice per year. Exdensur (depemokimab) is a long-acting interleukin-5 (IL-5) antagonist. It prevents IL-5 from activating its receptor on eosinophils, thereby reducing an overproduction of the white blood cells.
